Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer
Abstract This review focuses on patients with differentiated thyroid carcinoma (DTC) associated with multiple primary malignant neoplasm (MPMN) treated by multikinase inhibitors (MKIs) as systemic treatment for advanced disease. Despite the increasing frequency of MPMNs (many at an advanced stage) a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5107 |
| _version_ | 1817981123116924928 |
|---|---|
| author | Marcel Sambo |
| author_facet | Marcel Sambo |
| author_sort | Marcel Sambo |
| collection | DOAJ |
| description | Abstract This review focuses on patients with differentiated thyroid carcinoma (DTC) associated with multiple primary malignant neoplasm (MPMN) treated by multikinase inhibitors (MKIs) as systemic treatment for advanced disease. Despite the increasing frequency of MPMNs (many at an advanced stage) and the usefulness of MKIs for multiple metastatic cancers, published data on the management of MPMN and MKI therapies in this scenario are scarce. There are infrequent descriptions of patients with advanced MPMN treated with MKIs, but only a few have described advanced DTC. The management of MPMNs, including DTC and its particular circumstances, is reviewed, focusing on the evidence for MKI therapies. Some considerations for MPMN patients with advanced DTC are discussed, with the intention of helping physicians make decisions in these challenging situations and improving treatment and patient outcomes. |
| first_indexed | 2024-04-13T23:01:39Z |
| format | Article |
| id | doaj.art-5a6971fcb12b41f6a3f63836fbc09bb5 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-13T23:01:39Z |
| publishDate | 2022-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-5a6971fcb12b41f6a3f63836fbc09bb52022-12-22T02:25:48ZengWileyCancer Medicine2045-76342022-10-0111S1263210.1002/cam4.5107Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancerMarcel Sambo0Endocrinology and Nutrition Department General University Hospital Gregorio Maranon Madrid SpainAbstract This review focuses on patients with differentiated thyroid carcinoma (DTC) associated with multiple primary malignant neoplasm (MPMN) treated by multikinase inhibitors (MKIs) as systemic treatment for advanced disease. Despite the increasing frequency of MPMNs (many at an advanced stage) and the usefulness of MKIs for multiple metastatic cancers, published data on the management of MPMN and MKI therapies in this scenario are scarce. There are infrequent descriptions of patients with advanced MPMN treated with MKIs, but only a few have described advanced DTC. The management of MPMNs, including DTC and its particular circumstances, is reviewed, focusing on the evidence for MKI therapies. Some considerations for MPMN patients with advanced DTC are discussed, with the intention of helping physicians make decisions in these challenging situations and improving treatment and patient outcomes.https://doi.org/10.1002/cam4.5107differentiated thyroid carcinomamultikinase inhibitorsmultiple primary malignant neoplasmssynchronous/metachronous cancers |
| spellingShingle | Marcel Sambo Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer Cancer Medicine differentiated thyroid carcinoma multikinase inhibitors multiple primary malignant neoplasms synchronous/metachronous cancers |
| title | Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer |
| title_full | Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer |
| title_fullStr | Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer |
| title_full_unstemmed | Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer |
| title_short | Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer |
| title_sort | use of multikinase inhibitors lenvatinib in patients with synchronous metachronous cancers coinciding with radioactive resistant differentiated thyroid cancer |
| topic | differentiated thyroid carcinoma multikinase inhibitors multiple primary malignant neoplasms synchronous/metachronous cancers |
| url | https://doi.org/10.1002/cam4.5107 |
| work_keys_str_mv | AT marcelsambo useofmultikinaseinhibitorslenvatinibinpatientswithsynchronousmetachronouscancerscoincidingwithradioactiveresistantdifferentiatedthyroidcancer |